Opinion|Videos|October 14, 2024
Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC
Key Takeaways
- Urologists need oncologists to provide systemic therapy insights and manage immune-related adverse events in combination therapy.
- Oncologists rely on urologists for expertise in local disease management and patient selection for combination therapy.
Panelists discuss how urologists and oncologists must collaborate to improve outcomes for high-risk non–muscle-invasive bladder cancer (NMIBC) patients receiving combination therapy with PD-1/PD-L1 inhibitors and BCG, emphasizing the need for clear communication and coordinated care strategies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What do urologists need from oncologists, and vice versa, in improving outcomes for high-risk non–muscle-invasive bladder cancer patients for combination therapy with PD-1/PD-L1 inhibitors plus BCG?
Advertisement
Related to this article
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.
Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
2
Pasritamig combination yields 73% PSA response rate in phase 1 mCRPC study
3
FAQ: ASTRO guideline on hypofractionated radiation therapy for localized prostate cancer
4
Q&A: Suzanne B. Merrill, MD, FACS, on perioperative therapy in MIBC
5